Trust Co. of Vermont purchased a new stake in Amgen Inc. (NASDAQ:AMGN – Free Report) during the second quarter, according to its most recent filing with the SEC. The firm purchased 22,744 shares of the medical research company’s stock, valued at approximately $8,236,000.
A number of other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after buying an additional 961,975 shares during the period. State Street Corp raised its stake in Amgen by 4.4% during the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after buying an additional 1,287,310 shares during the period. Capital World Investors lifted its holdings in Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after acquiring an additional 4,302,237 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Amgen by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares in the last quarter. Finally, Norges Bank acquired a new position in Amgen in the fourth quarter valued at about $2,164,162,000. Institutional investors and hedge funds own 76.50% of the company’s stock.
Analyst Upgrades and Downgrades
AMGN has been the subject of several recent analyst reports. The Goldman Sachs Group set a $389.00 price target on Amgen in a report on Friday, June 5th. Sanford C. Bernstein lifted their price objective on Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a report on Thursday, August 6th. BMO Capital Markets boosted their price objective on Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Wells Fargo & Company increased their target price on Amgen from $390.00 to $400.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Finally, Bank of America lifted their price target on shares of Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $375.93.
Key Stories Impacting Amgen
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: Amgen’s recent results reinforced its growth narrative: quarterly revenue rose 9.5% year over year to $10.05 billion, while adjusted earnings of $6.29 per share exceeded consensus by $0.67. Management’s fiscal 2026 EPS guidance of $22.30–$23.50 also supports the bullish outlook. Amgen Results Put Growth Back in Focus
- Positive Sentiment: A completed Phase 1 study comparing two evolocumab formulations provides continued support for Amgen’s cholesterol franchise. Evolocumab, marketed as Repatha, is an important commercial product, and formulation work could help support its future development and patient use. Amgen’s Evolocumab Formulation Study
- Positive Sentiment: Growth-focused analysis from Zacks highlights Amgen’s earnings profile and potential for continued performance, adding to the favorable investor narrative. Why Amgen Is a Strong Growth Stock
- Neutral Sentiment: Cantor Fitzgerald raised its Amgen price target to $400 but retained a Neutral rating. Mizuho also maintained Neutral while lifting its target to $352, indicating that analysts see some fundamental improvement but believe the recent rally has exceeded their valuation expectations.
- Negative Sentiment: Amgen exercised its right to terminate a partnership with TScan Therapeutics, removing a collaboration from TScan’s pipeline. While the direct financial effect on Amgen is unclear, the termination may raise questions about partnership prioritization or the development prospects of the related program. TScan Therapeutics Faces Loss of Key Amgen Partnership
Amgen Stock Performance
Shares of Amgen stock opened at $425.28 on Wednesday. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The firm has a market cap of $229.92 billion, a price-to-earnings ratio of 26.43, a price-to-earnings-growth ratio of 3.86 and a beta of 0.41. The stock’s 50-day moving average is $373.66 and its 200-day moving average is $360.06. Amgen Inc. has a one year low of $269.77 and a one year high of $427.39.
Amgen (NASDAQ:AMGN – Get Free Report) last announced its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.Amgen’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter last year, the firm earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts predict that Amgen Inc. will post 22.78 earnings per share for the current fiscal year.
Amgen Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is currently 62.65%.
Insider Buying and Selling
In related news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 6,222 shares of company stock worth $2,540,926 over the last quarter. 0.85% of the stock is owned by corporate insiders.
Amgen Profile
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Featured Articles
- Five stocks we like better than Amgen
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
